Pfizer & Astellas Pharma announces positive results from phase 3 EMBARK study of Xtandi plus leuprolide in men with non-...
Pfizer Inc. and Astellas Pharma Inc. announced positive topline results from the overall survival (OS) analysis from the phase 3 EMBARK study evaluating Xtandi (enzalutamide), in combination with leuprolide and as a monotherapy, in men with non-metastatic …